65. McKenna, C., Wade, R., Farria, R., Yang, H., Stirk, L., Gummerson, N., Sculpher, M., Woolacott, N. EOS 2D/3D X-ray Imaging System - Technology Assessment Report <strong>for</strong> NICE - Diagnostics Assessment Report. 2011; available from http://www.nice.org.uk/nicemedia/live/13030/54603/54603.pdf (accessed Dec. 11 A.D.). 66. Kind, P., Dolan, P., Gudex, C., Williams, A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998; 316(7133):736-741. 67. Rivero-Arias, O., Ouellet, M., Gray, A., Wolstenholme, J., Rothwell, P.M., Luengo- Fern<strong>and</strong>ez, R. Mapping <strong>the</strong> modified Rankin scale (mRS) measurement into <strong>the</strong> generic EuroQol (EQ-5D) health outcome. Med Decis Making 2010; 30(3):341-354. 68. Locadia, M., Bossuyt, P.M., Stalmeier, P.F., Sprangers, M.A., van Dongen, C.J., Middeldorp, S. et al. Treatment <strong>of</strong> venous thromboembolism with vitamin K antagonists: patients' health state valuations <strong>and</strong> <strong>treatment</strong> preferences. Thromb Haemost 2004; 92(6):1336-1341. 69. Lenert, L.A., Soetikno, R.M. Automated computer interviews to elicit utilities: potential applications in <strong>the</strong> <strong>treatment</strong> <strong>of</strong> <strong>deep</strong> venous <strong>thrombosis</strong>. J Am Med In<strong>for</strong>m Assoc 1997; 4(1):49-56. 70. Meads, D.M., McKenna, S.P., Doughty, N., Das, C., Gin-Sing, W., Langley, J. et al. The responsiveness <strong>and</strong> validity <strong>of</strong> <strong>the</strong> CAMPHOR Utility Index. Eur Respir J 2008; 32(6):1513-1519. 71. van Asch, C.J., Luitse, M.J., Rinkel, G.J., van der Tweel, I., Algra, A., Klijn, C.J. Incidence, case fatality, <strong>and</strong> functional outcome <strong>of</strong> intracerebral haemorrhage over time, according to age, sex, <strong>and</strong> ethnic origin: a systematic review <strong>and</strong> meta-analysis. Lancet Neurol 2010; 9(2):167-176. 72. Marchetti, M., Pistorio, A., Barone, M., Serefini, S., Barosi, G. Low-molecularweight heparin versus warfarin <strong>for</strong> secondary prophylaxis <strong>of</strong> venous thromboembolism: a cost-effectiveness analysis. Am J Med 2001; 111(2):130-139. 73. O'Meara, J., McNutrt, R.A., Evans, A.T., Moore, S.W., Downs, S.M. A decision analysis <strong>of</strong> streptokinase plus heparin as compared with heparin alone <strong>for</strong> <strong>deep</strong>-<strong>vein</strong> <strong>thrombosis</strong>. N Engl J Med 1994; 330(26):1864-1869. 74. Meenan, R.T., Saha, S., Chou, R., Swarztrauber, K., Pyle Krages, K., O'Keeffe- Rosetti, M.C. et al. Cost-Effectiveness <strong>of</strong> Echocardiography to Identify Intracardiac Thrombus among Patients with First Stroke or Transient Ischemic Attack. Medical Decision Making 2007; 27(2):161-177. 75. Rachet, B., Ellis, L., Maringe, C., Chu, T., Nur, U., Quaresma, M. et al. Socioeconomic inequalities in cancer survival in Engl<strong>and</strong> after <strong>the</strong> NHS cancer plan. Br J Cancer 2010; 103(4):446-453. 76. Levitan, B., Yuan, Z., Turpie, A.G.G., Friedman, R.J., Homering, M., Berlin, J.A. et al. Quantitative benefit-risk assessment <strong>of</strong> rivaroxaban <strong>for</strong> <strong>the</strong> prevention <strong>of</strong> venous thromboembolism. Blood Conference: 51st Annual Meeting <strong>of</strong> <strong>the</strong> American Society <strong>of</strong> Hematology, ASH New Orleans, LA United States Conference Start: 20091205 Conference End: 20091208 Conference Publication: (Var Pagings) 114 (22) , 2009 Date <strong>of</strong> Publication: 20 Nov 2009(var.pagings):20. 187 Copyright 2012 Queen's Printer <strong>and</strong> Controller <strong>of</strong> HMSO. All rights reserved.
77. NICE Guidance. Atrial fibrillation - dabigatran etexilate. 2011; available from http://guidance.nice.org.uk/TA/Wave21/10 188 Copyright 2012 Queen's Printer <strong>and</strong> Controller <strong>of</strong> HMSO. All rights reserved.
- Page 1 and 2:
Rivaroxaban for the treatment of de
- Page 3 and 4:
TABLE OF CONTENTS List of Abbreviat
- Page 5 and 6:
Table 12 Time to therapeutic INR (I
- Page 7 and 8:
identified in the model). Table 40
- Page 9 and 10:
Figures Figure 1 Flow diagram for i
- Page 11 and 12:
Figure 23 Exploratory analysis in c
- Page 13 and 14:
MS Manufacturer’s submission NE S
- Page 15 and 16:
The dose of LMWH used reflects Amer
- Page 17 and 18:
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
- Page 19 and 20:
The exploratory analysis in cancer
- Page 21 and 22:
intended treatment duration of 12 m
- Page 23 and 24:
VTE therefore has a substantial bur
- Page 25 and 26:
indefinite treatment. VTE LMWH, low
- Page 27 and 28:
3 Critique of manufacturer’s defi
- Page 29 and 30:
Subgroups to be considered Special
- Page 31 and 32:
contraindications for the drug (as
- Page 33 and 34:
3.1.3 MTC populations The populatio
- Page 35 and 36:
3.2.2 Length of treatment As discus
- Page 37 and 38:
“No preventative therapy” is th
- Page 39 and 40:
It could be argued that poor TTR ma
- Page 41 and 42:
3.4.2 Outcomes recommended by EMA r
- Page 43 and 44:
4 CLINICAL EFFECTIVENESS 4.1 Critiq
- Page 45 and 46:
competitor products were excluded f
- Page 47 and 48:
Figure 1 Flow diagram for identifyi
- Page 49 and 50:
Table 7: Table showing list of rele
- Page 51 and 52:
The approach taken to quality asses
- Page 53 and 54:
o EINSTEIN-DVT dose-ranging study 3
- Page 55 and 56:
Trial name References, study type E
- Page 57 and 58:
4.2.1 Critique of pivotal EINSTEIN-
- Page 59 and 60:
However, the study design did not i
- Page 61 and 62:
Table 10: Summary of outcomes for E
- Page 63 and 64:
Chi-square analyses were undertaken
- Page 65 and 66:
clarification on this matter, the m
- Page 67 and 68:
Both of these factors are likely to
- Page 69 and 70:
It remains unclear why these patien
- Page 71 and 72:
leeding may be less suited to longe
- Page 73 and 74:
may account for the apparent differ
- Page 75 and 76:
Table 13: Criteria used to define a
- Page 77 and 78:
DVT and/or PE xxxxxxxxx xxxxxxxxxxx
- Page 79 and 80:
There is some doubt about the appro
- Page 81 and 82:
Subgroup analyses - EINSTEIN-Ext Su
- Page 83 and 84:
o It is clear that bleed events wer
- Page 85 and 86:
is likely to be small as the outcom
- Page 87 and 88:
depends on the specific parameteris
- Page 89 and 90:
4.4.3 Between study standard deviat
- Page 91 and 92:
Table 19.2: VTE recurrence (dichoto
- Page 93 and 94:
Table 22 Uncertainties in clinical
- Page 95 and 96:
The ERG are of the understanding th
- Page 97 and 98:
For the primary analysis, the rates
- Page 99 and 100:
In the economic model, the manufact
- Page 101 and 102:
Finally, in cancer patients, the ma
- Page 103 and 104:
Our experts believed that patients
- Page 105 and 106:
Similarly, the manufacturer used da
- Page 107 and 108:
Table 25: baseline risk of events f
- Page 109 and 110:
y intended treatment duration given
- Page 111 and 112:
eflect the current long term risk o
- Page 113 and 114:
survival of 70% in the 148 non-surg
- Page 115 and 116:
Monitoring xxxxxxxxxxxxxxxxxxxxxxxx
- Page 117 and 118:
The ERG acknowledges that the monit
- Page 119 and 120:
For patients managed in the inpatie
- Page 121 and 122:
The searches identified 2,811 poten
- Page 123 and 124:
The health state utility value for
- Page 125 and 126:
xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxx
- Page 127 and 128:
few occasions for both VTEs and ble
- Page 129 and 130:
2) the values used in the PSA for t
- Page 131 and 132:
5.2.1 Results included in the manuf
- Page 133 and 134:
Figure 8: Tornado plot - Net Moneta
- Page 135 and 136:
5.2.2.1.2. Results for patients for
- Page 137 and 138:
Figure 12: Cost-effectiveness plane
- Page 139 and 140:
Figure 14: Tornado plot - Net Monet
- Page 141 and 142:
5.2.2.2 Subgroup analysis - cancer
- Page 143 and 144:
Figure 17: Tornado plot - Net Monet
- Page 145 and 146:
5.2.3 Comment on validity of result
- Page 147 and 148: Table 36: Summary of uncertainties
- Page 149 and 150: Summary of uncertainties Has the im
- Page 151 and 152: Summary of uncertainties Has the im
- Page 153 and 154: Summary of uncertainties Has the im
- Page 155 and 156: Superseded - See Erratum 6. ADDITIO
- Page 157 and 158: Superseded - See Erratum Table 37 S
- Page 159 and 160: Superseded - See Erratum Table 38:
- Page 161 and 162: Superseded - See Erratum Table 42:
- Page 163 and 164: Superseded - See Erratum Figure 21:
- Page 165 and 166: Superseded - See Erratum Table 46:
- Page 167 and 168: Superseded - See Erratum 6.3. Proba
- Page 169 and 170: Superseded - See Erratum Table 50:
- Page 171 and 172: Superseded - See Erratum Table 54:
- Page 173 and 174: 6.5. Exploratory analysis in cancer
- Page 175 and 176: Figure 23: Exploratory analysis in
- Page 177 and 178: Table 60: Deterministic base case a
- Page 179 and 180: The ERG also examined the impact of
- Page 181 and 182: days after stopping treatment.(Bull
- Page 183 and 184: Both Phase II studies performed ana
- Page 185 and 186: Appendix 2 Correction of Tables 29
- Page 187 and 188: Appendix 3 Definition of `sufficien
- Page 189 and 190: A bullet on page 42 states that `53
- Page 191 and 192: Both numbers refer to the placebo a
- Page 193 and 194: 9. REFERENCES 1. Bayer PLC. Rivarox
- Page 195 and 196: http://www.dh.gov.uk/en/Publication
- Page 197: 51. Department of Health. NHS Refer